390 related articles for article (PubMed ID: 16641043)
1. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
Dahlqvist SR; Engstrand S; Berglin E; Johnson O
Scand J Rheumatol; 2006; 35(2):107-11. PubMed ID: 16641043
[TBL] [Abstract][Full Text] [Related]
2. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
[TBL] [Abstract][Full Text] [Related]
3. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
Cauza E; Cauza K; Hanusch-Enserer U; Etemad M; Dunky A; Kostner K
Wien Klin Wochenschr; 2002 Dec; 114(23-24):1004-7. PubMed ID: 12635469
[TBL] [Abstract][Full Text] [Related]
4. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
Kiortsis DN; Mavridis AK; Filippatos TD; Vasakos S; Nikas SN; Drosos AA
J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
[TBL] [Abstract][Full Text] [Related]
6. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
Vis M; Nurmohamed MT; Wolbink G; Voskuyl AE; de Koning M; van de Stadt R; Twisk JW; Dijkmans BA; Lems WF
J Rheumatol; 2005 Feb; 32(2):252-5. PubMed ID: 15693084
[TBL] [Abstract][Full Text] [Related]
7. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
[TBL] [Abstract][Full Text] [Related]
8. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis.
Allanore Y; Kahan A; Sellam J; Ekindjian OG; Borderie D
Clin Chim Acta; 2006 Mar; 365(1-2):143-8. PubMed ID: 16176811
[TBL] [Abstract][Full Text] [Related]
9. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.
García-Gómez C; Nolla JM; Valverde J; Narváez J; Corbella E; Pintó X
Eur J Clin Invest; 2008 Sep; 38(9):686-92. PubMed ID: 18837746
[TBL] [Abstract][Full Text] [Related]
10. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
11. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
12. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study.
Filippatos TD; Derdemezis CS; Voulgari PV; Tsimihodimos V; Elisaf MS; Tselepis AD; Drosos AA
Scand J Rheumatol; 2013; 42(3):169-75. PubMed ID: 23311768
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients.
Morris SJ; Wasko MC; Antohe JL; Sartorius JA; Kirchner HL; Dancea S; Bili A
Arthritis Care Res (Hoboken); 2011 Apr; 63(4):530-4. PubMed ID: 21452265
[TBL] [Abstract][Full Text] [Related]
14. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
15. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab.
Raterman HG; Levels H; Voskuyl AE; Lems WF; Dijkmans BA; Nurmohamed MT
Ann Rheum Dis; 2013 Apr; 72(4):560-5. PubMed ID: 22589377
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
17. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.
Peters MJ; Vis M; van Halm VP; Wolbink GJ; Voskuyl AE; Lems WF; Dijkmans BA; Twisk JW; de Koning MH; van de Stadt RJ; Nurmohamed MT
Ann Rheum Dis; 2007 Jul; 66(7):958-61. PubMed ID: 17314120
[TBL] [Abstract][Full Text] [Related]
18. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis.
Derdemezis CS; Filippatos TD; Voulgari PV; Tselepis AD; Drosos AA; Kiortsis DN
Fundam Clin Pharmacol; 2009 Oct; 23(5):595-600. PubMed ID: 19563510
[TBL] [Abstract][Full Text] [Related]
19. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
20. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
